|
|
|
|
|
Received: 10 January 2020
|
|
|
|
|
|
| [1] |
Wakefield B J, Busse L W, Khanna A K, et al. Angiotensin II in vasodilatory Shock[J]. Crit Care Clin, 2019, 35(2): 229-245.
|
| [2] |
Benbenishty J,Weissman C, Sprung C L,et al. Characteristics of patients receiving vasopressors[J] .Heart Lung, 2011, 40(3): 247-252.
|
| [3] |
Bassi E,Park M,Azevedo L C. Therapeutic strategies for high-dose vasopressor-dependent shock[J].Crit Care Res Pract, 2013, 2013: 654708.
|
| [4] |
Khanna A, English S W, Wang X S,et al. Angiotensin II for the treatment of vasodilatory shock[J]. New Engl J Med, 2017, 377(5): 419-430.
|
| [5] |
Walsh M, Devereaux P J, Garg A X, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension[J] .Anesthesiology, 2013, 119(3): 507-515.
|
| [6] |
Jentzer J C, Vallabhajosyula S, Khanna A K, et al. Management of refractory vasodilatory shock[J]. Chest, 2018, 154(2): 416-426.
|
| [7] |
Auchet T, Regnier M A, Girerd N, et al. Outcome of patients with septic shock and high-dose vasopressor therapy[J]. Ann Intensive Care, 2017, 7(1): 43.
|
| [8] |
Dünser M W, Mayr A J, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study[J]. Circulation, 2003, 107(18): 2313-2319.
|
| [9] |
Vallabhajosyula S, Jentzer J C, Khanna A K. Vasodilatory shock in the ICU: perils, pitfalls and therapeutic options[M]// Jean-Louis V. Annual Update in Intensive Care and Emergency Medicine, Springer. International Publishing, 2018:99-111.
|
| [10] |
Marik P E, Pastores S M, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine[J] .Crit Care Med, 2008, 36(6): 1937-1949.
|
| [11] |
Brown S M,Lanspa M J,Jones J P, et al. Survival after shock requiring high-dose vasopressor therapy[J] .Chest, 2013, 143(3): 664-671.
|
| [12] |
Cooper B E. Review and update on inotropes and vasopressors[J].AACN Adv Crit Care, 2008, 19(1): 5-13.
|
| [13] |
Dalimonte M A, DeGrado J R, Anger K E. Vasoactive agents for adult septic shock: an update and review[J]. J Pharm Pract, 2019, undefined: 897190019844124.
|
| [14] |
Khalique S C, Ferguson N. Angiotensin Ⅱ (Giapreza): a distinct mechanism for the treatment of vasodilatory shock[J] .Cardiol Rev, 2019, 27(3): 167-169.
|
| [15] |
Ham K R, Boldt D W, McCurdy M T, et al. Sensitivity to angiotensin Ⅱ dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial[J]. Ann Intensive Care, 2019, 9(1): 63.
|
| [16] |
DeBacker D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best?[J]. Crit Care Med, 2003, 31(6): 1659-1667.
|
| [17] |
Hollenberg S M. Vasopressor support in septic shock[J].Chest, 2007, 132(5): 1678-1687.
|
| [18] |
胡才宝,严 静. 感染性休克血管活性药物选择策略[J]. 中国实用内科杂志, 2015, 35(11): 900-903.
|
| [19] |
Wakefield B J, Sacha G L, Khanna A K. Vasodilatory shock in the ICU and the role of angiotensin Ⅱ[J].Curr Opin Crit Care, 2018, 24(4): 277-285.
|
| [20] |
Ukor I F, Walley K R. Vasopressin in vasodilatory shock[J]. Crit Care Clin, 2019, 35(2): 247-261.
|
| [21] |
Patel B M, Chittock D R, Russell J A, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock[J]. Anesthesiology, 2002, 96(3): 576-582.
|
| [22] |
Russell J A, Walley K R, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock[J]. N Engl J Med, 2008, 358(9):877-887.
|
| [23] |
Leone M, Albanèse J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients[J]. Shock, 2004, 22(4): 314-319.
|
| [24] |
Bissell B D, Browder K, McKenzie M, et al. A blast from the past: revival of angiotensin II for vasodilatory shock[J]. Ann Pharmacother, 2018, 52(9): 920-927.
|
| [25] |
Busse L W, Wang X S, Chalikonda D M, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety[J]. Crit Care Med, 2017, 45(8): 1285-1294.
|
| [26] |
Carr A C, Shaw G M, Fowler A A, et al. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?[J]. Crit Care, 2015, 19: 418.
|
| [27] |
Marik P E, Khangoora V, Rivera R, et al. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study[J].Chest, 2017, 151(6): 1229-1238.
|
|
|
2020, Vol. 31 
